The value chain that should carry the science from bench to bedside is broken in specific, identifiable places. It's a living framework, built to grow as the field matures. Every bottleneck is also an investment opportunity. This is the systemic view.
Read the chain left to right. Funding becomes research, research becomes trials, trials become the biomarkers and data a clinic can actually use, and the clinic is where a woman finally gets a real answer. That's how it should work. Today the handoff fails at all seven points, which is why so little reaches her. The flip side: every break is also where the capital and the builders should go. This map shows what's broken. It also shows where to build.
Reproductive longevity research is chronically underfunded relative to its disease burden.
The NIH historically allocated less than 11% of its research budget to conditions that exclusively or disproportionately affect women. No funding means no researchers, no trials, no data. Every other bottleneck downstream is a function of this one.
You cannot study what you cannot model.
Mice don't menopause naturally. It has to be artificially induced, which means the models are imperfect from the start. There are no good in-vitro models for the human ovary. The organ is extraordinarily complex and context-dependent.
Women were excluded from trials for decades and the exclusion outlived its justification.
Originally due to concerns about pregnancy, the practice persisted long after it was defensible. Female-specific trials are rare. Most drug and intervention data is extrapolated from male subjects and assumed to apply to women. It often does not.
No validated, standardized biomarker for ovarian aging.
AMH is the closest proxy, but it is imprecise and not predictive enough. Without good biomarkers, you cannot measure progression, you cannot run trials efficiently, and you cannot give women actionable data about their own biology.
Hormonal variability across the cycle gets treated as noise and edited out of the signal.
The female-specific infrastructure to capture longitudinal endocrine data simply does not exist at scale. Researchers avoid the cost of collecting it. The data gap compounds. Without infrastructure, the field cannot learn.
The science that exists doesn't reach the OB/GYN office fast enough.
Most OB/GYNs are not trained in longevity medicine. The gap between what the science knows and what a woman hears at her annual exam is enormous. Standard-of-care is set by what the average clinician learned ten years ago.
The therapy exists and the doctor offers it. Whether anyone will pay for it is a separate question.
Payers cover what sits in clinical guidelines and comes with health-economic evidence. Most reproductive longevity care has neither yet, so it gets classed as elective and billed to the woman herself. The cost math works against it too: treating ovarian aging early prevents expensive disease decades later, but the insurer paying today rarely captures that future saving. So the upstream work goes unfunded, and a proven therapy stays out of reach for anyone who can't pay out of pocket.
Women may not know they have a condition at all. Their symptoms got filed as normal.
It starts before anyone asks for a solution. A woman whose symptoms have been called normal doesn't know she has a condition at all, let alone what to measure or which questions to ask. No recognition means no demand, and no demand means no pressure on the system to change. This is the bottleneck I work on directly: translation and advocacy.
"Every bottleneck in the value chain is also an investment opportunity. The lack of good ovarian models is a biotech opportunity. The lack of biomarkers is a diagnostics opportunity. The clinical translation gap is a digital health opportunity."